Detalhe da pesquisa
1.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37354090
2.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636033
3.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
4.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388860
5.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474619
6.
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
Ann Hematol
; 97(9): 1577-1580, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675611
7.
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study.
Cancers (Basel)
; 14(3)2022 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158922
8.
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
Blood Cancer J
; 10(6): 66, 2020 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32514110
9.
Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.
Cancer Genet Cytogenet
; 199(2): 139-42, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20471518
10.
Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.
Surg Laparosc Endosc Percutan Tech
; 18(4): 426-8, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18716551